Crohn's disease: risk factor for colorectal cancer

Variables that were statistically significant across both analyses (longitudinal remission and drug durability) are indicated in bold in Table 2, and comprise the number of

Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. PIK3CA mutations in colorectal cancer

This review gives hand on recent advances of personalized oncology in several cancer disease models including leukemia, melanoma, breast cancer, lung cancer, colorectal cancer,

Persistent diarrhea in patients with Crohn’s disease after mucosal healing is associated with lower diversity of the intestinal microbiome and increased dysbiosis. Molecular

Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response

The analysis of low-frequency genetic variants mapping to the TNF signaling pathway using the SKAT-O test showed that the damaging burden is different between anti-TNF

NSAIDs increase the risk of cardiovascular disease in the general population, and although there is little direct evidence for elevated cardiovascular risk with NSAIDs in people

Keywords: immune system; dysbiosis; inflammatory bowel disease; Crohn’s disease; ulcerative colitis;